Lupus (SLE): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 80
• BCMA 38
• STING 0
• CD20 9
• SGLT2 3
• STAT3 0
• NLRP3 0
• mTOR 0
• JAK 0
• TNF 0
• IL-17 1
• IL-6 0
• PI3K 0
• CD40 0
• TYK2 0
• CTLA-4 0
• FOXP3 0
• PD-1 0
• PPAR 0
• AMPK 0
• CD38 1
• IL-1 0
• NRF2 0
• TP53 0
• AKT 0
• AQP4 0
• CD22 1
• CXCR4 0
• IL-23 0
• APOL1 0
• BRD4 0
• BTK 0
• CTNNB1 0
• GPX4 0
• HIF-1 0
• HMGB1 0
• IL-15 1
• MAPK 0
• PD-L1 0
• SIRT1 0
• TIGIT 0
• TLR4 0
• ANGPTL3 0
• BCL-2 0
• CD123 0
• COX-2 0
• DPP-4 0
• ERK 0
• EZH2 0
• FGFR 0
• FTO 0
• G6PD 0
• GLP-1 0
• IDO1 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MDM2 0
• METTL3 0
• MYC 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 37+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Terminated

  KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

  NCT06342960· Kyverna Therapeutics· Updated 31 Aug 2026

  “Study discontinued due to sponsor decision.”Registry text, quoted unchanged. Source

• Withdrawn

  UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

  NCT07410377· The Affiliated Hospital of Xuzhou Medical University· Updated 28 May 2026

  “Internal decision.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

  NCT06913608· Calibr, a division of Scripps Research· Updated 5 Mar 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

  NCT06549296· Nanjing Bioheng Biotech Co., Ltd.· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Suspended

  Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

  NCT06310811· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Terminated

  IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

  NCT06462144· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Updated 28 Jan 2026

  “The collaborating party has adjusted its R\&D strategy and terminated the study.”Registry text, quoted unchanged. Source

• Withdrawn

  CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

  NCT06752876· Caribou Biosciences, Inc.· Updated 19 Sept 2025

  “Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

  NCT06429800· Atara Biotherapeutics· Updated 24 Apr 2025

  “Financial”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

  NCT06377228· Takeda· Updated 6 Apr 2025

  “Business decision (no safety concerns)”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE)

  2024-519278-37-00· Celgene Corp.· Source

• A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

  NCT07873931· Bristol-Myers Squibb· Source

• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

  NCT05869955· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  NCT07115745· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

  NCT07371468· GlaxoSmithKline· Source

• KN5501 Cell Injection for Refractory SLE(CLEAR)

  NCT07358988· Ruitherapeutics Co., LTD· Source

• Allogeneic UCB-derived CAR-T for SLE

  NCT07274059· Chengdu Ucello Biotechnology Co., Ltd.· Source

• CD19/BCMA CAR-T for SLE

  NCT07266337· Chengdu Ucello Biotechnology Co., Ltd.· Source

• An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

  NCT06503224· The First Affiliated Hospital of University of Science and Technology of China· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Mendelian Randomization Analysis 41
• CRISPR-Cas Systems 1
• Gene Expression Profiling 101
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 35
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 35
• Immunohistochemistry 8
• Liquid Biopsy 2
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 49
• Machine Learning 37
• Deep Learning 3
• Cohort Studies 111
• Genome-Wide Association Study 54

See which targets of this disease your abstract mentions, and go to the people working on them.